Jin-Hee Ahn Selected Research

ErbB Receptors (EGF Receptor)

4/2022	Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
2/2022	CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience.
8/2021	Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab.
12/2018	A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
11/2018	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).
1/2018	Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
10/2015	Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcinoma or mutated EGFR.
2/2015	Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.
7/2011	Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea.
8/2004	Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jin-Hee Ahn Research Topics

Disease

73	Breast Neoplasms (Breast Cancer) 12/2022 - 06/2004
47	Neoplasms (Cancer) 12/2022 - 06/2004
13	Renal Cell Carcinoma (Grawitz Tumor) 04/2016 - 10/2010
12	Neoplasm Metastasis (Metastasis) 12/2021 - 07/2011
10	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 12/2011
9	Triple Negative Breast Neoplasms 10/2022 - 07/2011
8	Pathologic Complete Response 01/2022 - 06/2012
7	Disease Progression 04/2022 - 10/2012
5	Stomach Neoplasms (Stomach Cancer) 01/2021 - 08/2002
4	Neutropenia 01/2021 - 05/2012
3	Pain (Aches) 08/2020 - 01/2019
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2015 - 08/2004
3	Residual Neoplasm 06/2015 - 05/2014
2	Aggressive Fibromatosis (Desmoid) 10/2022 - 05/2021
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 02/2003
2	Leiomyosarcoma 01/2022 - 01/2018
2	Circulating Neoplastic Cells 03/2021 - 10/2020
2	Emergence Delirium 08/2020 - 01/2020
2	Hand-Foot Syndrome 01/2019 - 10/2004
2	Tertiary Lymphoid Structures 12/2015 - 08/2015
2	Adenocarcinoma 10/2015 - 03/2010
2	Carcinoma (Carcinomatosis) 08/2015 - 10/2012
2	Amenorrhea 09/2013 - 01/2011
2	Rectal Neoplasms (Rectal Cancer) 11/2011 - 04/2002
2	Brain Neoplasms (Brain Tumor) 07/2011 - 10/2008
2	Prostatic Neoplasms (Prostate Cancer) 04/2011 - 03/2010
1	Margins of Excision 04/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 02/2022
1	Liposarcoma 01/2022

Drug/Important Bio-Agent (IBA)

18	Hormones (Hormone)IBA 04/2022 - 03/2010
15	Docetaxel (Taxotere)FDA Link 01/2022 - 10/2004
13	Trastuzumab (Herceptin)FDA Link 01/2022 - 04/2012
13	AnthracyclinesIBA 01/2019 - 08/2004
11	Paclitaxel (Taxol)FDA LinkGeneric 10/2022 - 01/2009
10	ErbB Receptors (EGF Receptor)IBA 04/2022 - 08/2004
10	Tyrosine Kinase InhibitorsIBA 01/2020 - 01/2012
9	Biomarkers (Surrogate Marker)IBA 01/2022 - 08/2015
9	Gemcitabine FDA Link 01/2022 - 03/2012
9	human ERBB2 proteinIBA 08/2021 - 04/2012
8	Estrogen ReceptorsIBA 12/2022 - 06/2011
8	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2022 - 02/2005
7	Everolimus FDA Link 04/2022 - 12/2013
7	taxaneIBA 01/2021 - 08/2004
6	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2022 - 01/2009
6	Cisplatin (Platino)FDA LinkGeneric 10/2012 - 08/2002
5	Carboplatin (JM8)FDA LinkGeneric 10/2022 - 02/2005
5	Letrozole (Femara)FDA LinkGeneric 05/2021 - 10/2016
5	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 04/2016 - 04/2012
5	Sunitinib (Sutent)FDA Link 09/2013 - 01/2009
4	Tamoxifen FDA LinkGeneric 04/2021 - 08/2016
4	Lapatinib (GW572016)FDA Link 10/2020 - 10/2016
4	Epidermal Growth Factor (EGF)IBA 10/2020 - 07/2011
4	Vinorelbine (Navelbine)FDA LinkGeneric 12/2019 - 08/2004
4	Capecitabine (Xeloda)FDA Link 01/2019 - 08/2004
4	Angiogenesis InhibitorsIBA 12/2017 - 01/2014
4	Progesterone Receptors (Progesterone Receptor)IBA 10/2014 - 06/2004
3	eribulin FDA Link 01/2022 - 11/2017
3	pertuzumabIBA 01/2022 - 12/2018
3	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2016
3	Phenobarbital (Luminal)FDA Link 12/2021 - 05/2014
3	Pharmaceutical PreparationsIBA 01/2019 - 05/2012
3	thiamine triphosphorate (TTP)IBA 11/2018 - 08/2014
3	orantinib (SU6668)IBA 12/2017 - 08/2014
2	Indicators and Reagents (Reagents)IBA 10/2022 - 06/2012
2	Leuprolide (Lupron)FDA LinkGeneric 05/2021 - 01/2021
2	Alanine Transaminase (SGPT)IBA 01/2021 - 08/2016
2	CytokinesIBA 01/2021 - 06/2015
2	Zoledronic Acid (Zometa)FDA Link 01/2021 - 01/2011
2	Fulvestrant (Faslodex)FDA Link 11/2018 - 06/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 01/2015
2	HLA-A Antigens (HLA-A)IBA 05/2016 - 08/2015
2	ParaffinIBA 03/2016 - 06/2004
2	Gefitinib (Iressa)FDA Link 10/2015 - 06/2013
2	Ifosfamide FDA LinkGeneric 12/2013 - 03/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2012 - 01/2012
2	Estrogens (Estrogen)FDA Link 06/2012 - 06/2004
2	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 06/2005 - 02/2005
2	Fluorouracil (Carac)FDA LinkGeneric 02/2003 - 08/2002
1	RNA (Ribonucleic Acid)IBA 10/2022
1	Imatinib Mesylate (Gleevec)FDA Link 10/2022
1	CateninsIBA 10/2022
1	Epirubicin (Ellence)FDA LinkGeneric 10/2022
1	pembrolizumabIBA 10/2022
1	B7-H1 AntigenIBA 04/2022
1	Cyclin-Dependent Kinase 4IBA 04/2022
1	trastuzumab deruxtecanIBA 02/2022
1	atezolizumabIBA 01/2022

Therapy/Procedure

36	Drug Therapy (Chemotherapy) 10/2022 - 04/2002
24	Therapeutics 10/2022 - 04/2002
23	Neoadjuvant Therapy 10/2022 - 06/2012
13	Adjuvant Chemotherapy 01/2022 - 06/2004
12	Radiotherapy 04/2022 - 04/2002
6	Combination Drug Therapy (Combination Chemotherapy) 11/2017 - 10/2004
3	Immunotherapy 01/2022 - 05/2013
3	Nephrectomy 05/2013 - 01/2011
2	Mastectomy (Mammectomy) 01/2022 - 12/2021
2	Anesthesia 08/2020 - 01/2020
2	Maintenance Chemotherapy 07/2015 - 05/2013
2	Stem Cell Transplantation 06/2005 - 02/2005
1	Mammaplasty (Breast Reconstruction) 01/2022